Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 8/20 | 0.39 |
| ▸ | CTSK | P43235 | 8/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26575789 | 0.87 | HTT (0.41) | CTSSCTSKKDM4EGFER | |
| SCHEMBL6642572 | 0.80 | KDM4A (0.43) | KDM4ACTSKKDM4ELMNAL3MBTL1 | |
| SCHEMBL16020327 | 0.80 | KDM4A (0.43) | KDM4ACTSSCTSKKDM4ELMNA | |
| SCHEMBL25363898 | 0.80 | KDM4A (0.37) | KDM4ACTSSCTSKPTPN11CTSL | |
| SCHEMBL19558822 | 0.79 | KDM4A (0.42) | KDM4ACTSKKDM4ELMNAL3MBTL1 | |
| SCHEMBL5879612 | 0.78 | GPR35 (0.34) | — | |
| SCHEMBL18136849 | 0.78 | KDM4A (0.41) | KDM4ACTSKKDM4ELMNAL3MBTL1 | |
| SCHEMBL8218042 | 0.78 | KDM4A (0.41) | KDM4ACTSKKDM4ELMNAL3MBTL1 | |
| SCHEMBL25363398 | 0.78 | DAO (0.51) | KDM4ACTSKKDM4ELMNAL3MBTL1 | |
| SCHEMBL15873920 | 0.78 | KDM4A (0.41) | KDM4ACTSSCTSKPTPN11CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20120190832-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | ABBOTT GMBH & CO. KG (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20110071285-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | ABBOTT GMBH & CO. KG (DE) | 2011-03-24 | — | — | US | disclosed |
| EP-1169338-B1 | LOW-MOLECULAR INHIBITORS OF COMPLEMENT PROTEASES | ABBOTT GMBH & CO KG (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-20040048815-A1 | Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals | ABBOTT GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| US-6683055-B1 | GUANIDINE OR AMIDINE TERMINED PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-27 | — | — | US | disclosed |
| EP-1370573-A2 | LOW MOLECULAR SERINE PROTEASE INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | Abbott GmbH & Co. KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002030940-A2 | LOW MOLECULAR SERINE PROTEASE INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | ABBOTT GMBH & CO. KG (DE) | 2002-04-18 | — | — | WO | disclosed |
| EP-1169338-A2 | LOW-MOLECULAR INHIBITORS OF COMPLEMENT PROTEASES | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061608-A2 | LOW-MOLECULAR INHIBITORS OF COMPLEMENT PROTEASES | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071285-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | F2R, C1R, PRSS1 | KDM4A 2772/4885CTSS 39/4885CTSK 109/4885 |
| US-20040048815-A1 | Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals | F2R, C1R, PRSS1 | KDM4A 3008/4885CTSS 41/4885CTSK 99/4885 |
| US-20120190832-A1 | LOW-MOLECULAR SERINE PROTEASES INHIBITORS COMPRISING POLYHYDROXY-ALKYL AND POLYHYDROXY-CYCLOALKYL RADICALS | F2R, C1R, PRSS1 | KDM4A 2772/4885CTSS 39/4885CTSK 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.